Multiplex Biomarker Imaging Market
Market Insights on Multiplex Biomarker Imaging covering sales outlook, demand forecast & up-to-date key trends
Multiplex Biomarker Imaging Market by Component Type (Instruments, Software and Services), Imaging Technique (Immunohistochemistry (IHC) Assay, Fluorescent in Situ Hybridization (FISH) Assay and Tissue Microarray (TMA) Assay) & Region - Forecast 2022 - 2029
Multiplex Biomarker Imaging Market Snapshot
[280 Pages Report] The global Multiplex Biomarker Imaging Market was valued at US$ 422.1 Mn in 2021 and is expected to reach US$ 1,041.7 Mn by 2029, finds Future Market Insights (FMI) in a recent market survey.
|
Data Points |
Market Insights |
|
Market Value 2022 |
USD 475.2 Mn |
|
Market Value 2029 |
USD 1,041.7 Mn |
|
CAGR 2022-2029 |
11.9% |
|
Key Players |
The key players are PerkinElmer Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Abcam plc., Merck KGaA, Illumina Inc., Leica Biosystems Nussloch GmbH (Danaher Corporation), Ventana Medical Systems, Inc. (A F. Hoffmann-La Roche AG Subsidiary), Aushon BioSystems Ltd., MicroConstants, Inc., and ToposNomos Ltd. (TNL) |
|
Share of Top 5 Countries |
70.7% |
The growing prevalence of tumor and cancer among population around the world and increasing demand for more effective treatment and medicine for different types of cancer are primary factors fueling the multiplex biomarker imaging market.
In addition, the growing adoption of personalized medicine is expected to drive the growth of multiplex biomarker imaging market. Moreover, availability of technologically advanced instruments is likely to add to the market development.
Multiplex biomarker imaging market holds nearly 1.6% market value share of the US$ 31 Bn biomarkers market in 2021. An increase in production base of multispectral imaging devices that could provide multiplexing is expected to fuel the revenue growth of device manufacturers.
Leading manufacturers of multiplex biomarker imaging are also focusing on collaborations with laboratories and biopharmaceutical companies in order to expand sales presence.
Driven by this, sales of multiplex biomarker imaging are expected to rise at an 11.9% CAGR through 2029.
Let us know your requirement to get
100% FREE customization
How The Market Progressed Till June 2022?
|
Particulars |
Details |
|
H1, 2021 |
11.88% |
|
H1, 2022 Projected |
11.86% |
|
H1, 2022 Outlook |
11.76% |
|
BPS Change - H1, 2022 (O) – H1, 2022 (P) |
(-) 10 ↓ |
|
BPS Change – H1, 2022 (O) – H1, 2021 |
(-) 12 ↓ |
The multiplex biomarker imaging market is subject to influence by the rising inpatient base with tumors, and technological developments by the impact of macro and industry factors. FMI presents a comparative analysis of the market growth rates and development prospects in the global multiplex biomarker imaging market.
According to Future Market Insight analysis, the multiplex biomarker imaging market will drop by 12 Basis Point Share (BPS) in H1-2022 (O) compared to H1-2021. The preservation of discrete microenvironment morphology may be compromised in multiplex biomarker imaging due to lack of resolution or because of sampling time, it is difficult to preserve the immunelabeling with morphology.
This is the major reason for the drop in BPS attributed to the decline in shares. H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 10 BPS.
Despite the factors, some plus points stay ahead for the industry including technological advancements such as faster scanning time and higher sensitivity and emerging players entering into supply and distributor partnerships to expand their market reach.
2012-2021 Multiplex Biomarker Imaging Market Demand Outlook Compared to 2022-2029 Forecast
Sales of multiplex biomarker imaging grew at a CAGR of 13.5% between 2012 and 2021.
The multiplex biomarker imaging market is expected to show rapid growth owing to increasing prevalence of chronic diseases, rising adoption of personalized medicine, and a broad range of benefits of multiplex imaging over traditional imaging.
In addition, high prevalence of cardiac and cancer problems, advancements of biomarkers and increased application are the key factors contributing to the market development. The surge in cancer cases worldwide has led to increase in use of biomarkers with development in technology. As per the WCRF (World Cancer Research Fund International), about 18 million cases were there across the world in 2020. Also, the global burden of cancer cure and prevention is of the chief concern for the pharmaceutical and governments companies.
Considering this, FMI expects the global multiplex biomarker imaging market to grow at a CAGR of 11.9% through 2029.
Which Factors Are Restraining Demand for Multiplex Biomarker Imaging?
The complexity of the process and unclear regulatory guidance on the commercial sale of digital pathology imaging products are anticipated to hamper the multiplex biomarker imaging market growth. There is unclear regulatory control on commercial diagnostic use of whole slide imaging (WSI) products comprising multiplex biomarker imaging systems.
In addition, lack of awareness regarding multiplex biomarker imaging and cloud-enabled technologies, especially in developing countries, is restraining growth of the market. Also, the high cost of the multiplex biomarker imaging devices is prohibiting the adoption of these devices in research laboratories dealing with cancer research.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat is the Impact of the COVID-19 Crisis on the Multiplex Biomarker Imaging Market?
The coronavirus continues its march around the globe, disrupting nearly every business around the world. The market observed a huge slowdown in its growth due to the spread of Covid-19 pandemic worldwide.
As a result of pandemic related lockdowns in different countries and disruptions in the supply chain of medical equipment, the multiplex biomarker imaging market witnessed a drop during the lockdown period.
Also, the manufacturers encountered several operational challenges that initially hampered their business activities during the lockdown. Ultimately, with the relaxing of the lockdown and exceptional demand of the diagnosis, the sales of the multiple companies have grown positively. But, in the case of the multiplex biomarker imaging market, as these are playing a vital role in the development of therapies for chronic diseases, where pharmaceutical and government industries is expected to spend a lot, the market is expected to boost during the forecast period.
Country-wise Insights
What Makes the U.S. a Large Market for Multiplex Biomarker Imaging?
The U.S. is estimated to account for around 91.3% of the North America multiplex biomarker imaging market in 2022.
The growing prevalence of chronic diseases, like cancer, rising demand for personalized and targeted medicine, favorable government initiatives, and growing aging population are the key factors contributing to the growth of the market in U.S. The development can also be due to the availability of sophisticated diagnostics laboratories and great adoption rate of novel assay technologies. In addition, nearly every pharmaceutical manufacturer has been developing molecular biomarker products, either through different ventures or through partnerships.
Why is Germany Considered a Lucrative Multiplex Biomarker Imaging Market?
Germany is estimated to account for 20.2% of the Europe multiplex biomarker imaging market in Europe in 2022.
The growth of the market in Germany is because of the growing demand for automated equipment and commercialization of multipurpose instruments with cloud-enabled technologies in many labs and research facilities. In addition, growing cancer research funding by biotech and pharmaceutical companies is leading to increased biomarker discovery which is contributing to the market development. Also, growing prevalence of cancer is resulting into greater adoption of these biomarkers for early diagnosis which is increasing the demand for the market in Germany.
What are the Factors Fueling the Demand for Multiplex Biomarker Imaging in Japan?
The multiplex biomarker imaging market in Japan is estimated to be worth US$ 21.8 Mn in 2022 in the global market.
The major factors responsible for the development of the market in Japan are existence of a huge patient pool, rising focus on efficient and rapid diagnostics because of rising incidence of chronic diseases, presence of manufacturers in Japan and increasing investment to improve robust healthcare facilities.
Moreover, rising awareness concerning the significance of biomarkers in clinical diagnostics, developments in drug discovery and manufacturing processes, and growing clinical studies to understand the role of biomarkers in prognosis and diagnosis of complex diseases is expected to have a favorable effect on growth of the market.
How will the Multiplex Biomarker Imaging Market Expand across India?
Demand for multiplex biomarker imaging in India is expected to rise at around 6.6% CAGR over the forecast period.
Increased focus on cancer research and increased demand for testing of non-small cell lung cancer are primary factors leading to the growth of the market in India. There is increased focus on cancer research in India. Also, there is increased awareness for better diagnosis and focus on establishment of better research facilities in the country. Thus, increased access to better healthcare and diagnostic infrastructure and establishment of translational laboratories are factors fueling the demand for better imaging systems.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Category-wise Insights
Demand for Instruments to continue gaining Traction
By component type, instruments segment is anticipated to hold the maximum share of 73.9% in 2022, expanding at rate of nearly 11.8% during the forecast period.
The advantages offered by instruments like reliability, high image quality, and speed for entire slide imaging are encouraging the companies towards these instrument. Moreover, assessable pathology imaging systems, even though in their nascent stage, are adding to the potential sales forecasts for market players. Growing funding to develop advanced clinical and research laboratories has led to an increase in purchase of these instruments, which is anticipated to contribute to development of the segment.
Why Immunohistochemistry (IHC) Assay will hold the most of the market share?
By imaging technique, Immunohistochemistry (IHC) Assay will lead the market and is projected to account for 66.5% of the total market revenue share in 2022.
IHC is a histological method for identifying and localizing proteins in tissue specimens. This assay identifies some biomarkers such as oxidative stress, inflammation, tumors, and other diseases which assist in the diagnosis of complex diseases such as cancer using advanced methods. Thus, considering efficiency in regards to accuracy and processing time during detection of target proteins in tissue specimens, immunohistochemistry (IHC) assays is expected to lead the market over the forecast period.
Which application is most sought-after over the forecast period?
By application, research will be the most sought-after application and is projected to account for 86.5% of the total market revenue share in 2022.
Biomarkers are vital in medicine and play a significant role in research activities such as drug discovery and development. These can determine drug efficacy at a rapid pace in comparison to traditional clinical endpoints and is expected to fuel the product development for serious disease indications. Thus, good success rates of biomarkers in drug discovery is increasing its application in research, which in turn is leading to segment growth.
Why Translational Laboratories projected maximum growth in the Multiplex Biomarker Imaging Market?
By end user, translational laboratories segment is anticipated to hold the maximum share of 47.8% in 2022, expanding at rapid rate of 15.3% CAGR during the forecast period.
Multiplex Biomarker Imaging is utilized in translation laboratories as they offer a high-resolution methodology for creating immunohistochemistry images and precise scores of biomarkers. This method also aids to speed up the procedure by decreasing the amount of slides needed per marker, which leads to time-saving while performing analysis.
Competitive Landscape
Companies operating in the Multiplex Biomarker Imaging market are moderately competitive by nature, with a presence of few players. These players are involved in a number of strategic alliances. The product launch and acquisition accelerates the manufacturer’s strategy to capitalize on the market share and capture the significant share of market. Some of the recent instances include:
- In April 2021, Abcam, formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key companion and in vitro diagnostic kits for MEDx to supply to the Chinese market.
Scope of the Report
|
Attribute |
Details |
|
Forecast Period |
2012-2021 |
|
Historical Data Available for |
2022-2029 |
|
Market Analysis |
USD Million for Value and Units for Volume |
|
Key Countries Covered |
US, Canada, Brazil, Mexico, Germany, Argentina, U.K., Germany, France, Italy, Spain, Nordic, Benelux, Russia, Poland, China, Japan, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, South Africa |
|
Key Segments Covered |
Component Type, Imaging Technique, Application, End User and Region |
|
Key Companies Profiled |
|
|
Report Coverage |
Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
|
Customization & Pricing |
Available upon Request |
Multiplex Biomarker Imaging Market by Category
By Component Type:
- Instruments
- Quantitative Pathology Imaging System
- Immunofluorescence
- Multispectral Imaging System
- Toponome Imaging System
- Software
- Services
- Installation and Integration Services
- Maintenance Services
By Imaging Technique:
- Immunohistochemistry (IHC) Assay
- Fluorescent In Situ Hybridization (FISH) Assay
- Tissue Microarray (TMA) Assay
By Application:
- Research
- Clinical Diagnostics
By End User:
- Translation Laboratories
- Biopharmaceutical Companies
- Academic Institutes
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan (APEJ)
- Japan
- Middle East and Africa
Frequently Asked Questions
The global multiplex biomarker imaging market is worth US$ 422.1 Mn in 2021 and is set to expand 2.2X over the forecasted years owing to the rising cancer research and growing demand for personalized medicine.
The sales of Multiplex Biomarker Imaging in the market have grown at a CAGR of nearly 13.5% between 2012 and 2021. Increasing prevalence of chronic diseases and development in imaging assays is responsible for growth over the years.
The multiplex biomarker imaging market is expected to reach US$ 1,041.7 Mn by the end of 2029 with sales revenue expected to register CAGR of 11.9% over the forecast period.
North America currently holds the largest market share of around 57.0% in 2022 in the multiplex biomarker imaging market globally with U.S. being the leading contributor with a market value over US$ 247.3 Mn in North America market in 2022.
Demand of multiplex biomarker imaging market is expected to register growth in Western Europe at rate of 11.3% CAGR during the forecast period.
The Multiplex Biomarker Imaging in Japan is likely to observe growth with an impressive CAGR of 11.7% during the forecast period. The major factors responsible for the development of the market in Japan are existence of a huge patient pool, rising focus on efficient and rapid diagnostics because of rising incidence of chronic diseases, presence of manufacturers in Japan and increasing investment to improve robust healthcare facilities.
Growing adoption of IHC processes in immunofluorescence imaging and rising demand for large data set analysis are key trends driving sales of multiplex biomarker imaging market across the globe.
China’s Multiplex Biomarker Imaging market is offering lucrative growth opportunities and is expected to exhibit healthy growth of 12.0% CAGR during the forecast period. India market expected to exhibit healthy growth of 6.6% CAGR during the forecast period.
U.S., Germany, Canada, Japan and U.K. are the top 5 countries that are driving the demand for multiplex biomarker imaging market.
Leading companies of multiplex biomarker imaging are PerkinElmer Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Abcam plc., Merck KGaA, Illumina Inc., Leica Biosystems Nussloch GmbH (Danaher Corporation), Ventana Medical Systems, Inc. (A F. Hoffmann-La Roche AG Subsidiary), Aushon BioSystems Ltd., MicroConstants, Inc., and ToposNomos Ltd. (TNL)
Table of Content
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Trends
3.4. Restrains
3.5. Pricing Analysis 2021 and 2029
4. North America Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029
4.1. Introduction
4.2. Regional Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
4.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2021
4.3.1. U.S.
4.3.2. Canada
4.4. Market Size (US$ Mn) Forecast By Country, 2022–2029
4.4.1. U.S.
4.4.2. Canada
4.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021
4.5.1. Instruments
4.5.1.1. Quantitative Pathology Imaging System
4.5.1.2. Immunofluorescence Slide Scanner
4.5.1.3. Multispectral Imaging Systems
4.5.1.4. Toponome imaging System
4.5.2. Software
4.5.3. Services
4.5.3.1. Installation & Integration Services
4.5.3.2. Maintenance Service
4.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029
4.6.1. Instruments
4.6.1.1. Quantitative Pathology Imaging System
4.6.1.2. Immunofluorescence Slide Scanner
4.6.1.3. Multispectral Imaging Systems
4.6.1.4. Toponome imaging System
4.6.2. Software
4.6.3. Services
4.6.3.1. Installation & Integration Services
4.6.3.2. Maintenance Service
4.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021
4.7.1. Immunohistochemistry (IHC) Assay
4.7.2. Fluorescent In Situ Hybridization (FISH) Assay
4.7.3. Tissue Microarray (TMA) Assay
4.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029
4.8.1. Immunohistochemistry (IHC) Assay
4.8.2. Fluorescent In Situ Hybridization (FISH) Assay
4.8.3. Tissue Microarray (TMA) Assay
4.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
4.9.1. Research
4.9.2. Clinical Diagnostics
4.10. Market Size (US$ Mn) Forecast, by Application, 2022–2029
4.10.1. Research
4.10.2. Clinical Diagnostics
4.11. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
4.11.1. Translational Laboratories
4.11.2. Biopharmaceutical Companies
4.11.3. Academic Institutes
4.12. Market Size (US$ Mn) Forecast, by Application, 2022–2029
4.12.1. Translational Laboratories
4.12.2. Biopharmaceutical Companies
4.12.3. Academic Institutes
4.13. Drivers and Restraints: Impact Analysis
4.14. Market Attractiveness Analysis
4.14.1. By Country
4.14.2. By Component Type
4.14.3. By Imaging Technique
4.14.4. Application
4.14.5. End User
4.15. Key Representative Market Presence (Intensity Map)
5. Latin America Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2021
5.3.1. Brazil
5.3.2. Mexico
5.3.3. Argentina
5.3.4. Rest of Latin America
5.4. Market Size (US$ Mn) Forecast By Country, 2022–2029
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Argentina
5.4.4. Rest of Latin America
5.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021
5.5.1. Instruments
5.5.1.1. Quantitative Pathology Imaging System
5.5.1.2. Immunofluorescence Slide Scanner
5.5.1.3. Multispectral Imaging Systems
5.5.1.4. Toponome imaging System
5.5.2. Software
5.5.3. Services
5.5.3.1. Installation & Integration Services
5.5.3.2. Maintenance Service
5.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029
5.6.1. Instruments
5.6.1.1. Quantitative Pathology Imaging System
5.6.1.2. Immunofluorescence Slide Scanner
5.6.1.3. Multispectral Imaging Systems
5.6.1.4. Toponome imaging System
5.6.2. Software
5.6.3. Services
5.6.3.1. Installation & Integration Services
5.6.3.2. Maintenance Service
5.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021
5.7.1. Immunohistochemistry (IHC) Assay
5.7.2. Fluorescent In Situ Hybridization (FISH) Assay
5.7.3. Tissue Microarray (TMA) Assay
5.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029
5.8.1. Immunohistochemistry (IHC) Assay
5.8.2. Fluorescent In Situ Hybridization (FISH) Assay
5.8.3. Tissue Microarray (TMA) Assay
5.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
5.9.1. Research
5.9.2. Clinical Diagnostics
5.10. Market Size (US$ Mn) Forecast, by Application, 2022–2029
5.10.1. Research
5.10.2. Clinical Diagnostics
5.11. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
5.11.1. Translational Laboratories
5.11.2. Biopharmaceutical Companies
5.11.3. Academic Institutes
5.12. Market Size (US$ Mn) Forecast, by Application, 2022–2029
5.12.1. Translational Laboratories
5.12.2. Biopharmaceutical Companies
5.12.3. Academic Institutes
5.13. Drivers and Restraints: Impact Analysis
5.14. Market Attractiveness Analysis
5.14.1. By Country
5.14.2. By Component Type
5.14.3. By Imaging Technique
5.14.4. Application
5.14.5. End User
5.15. Key Representative Market Presence (Intensity Map)
6. Western Europe Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.2.3. Trends
6.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2021
6.3.1. U.K.
6.3.2. Germany
6.3.3. France
6.3.4. Italy
6.3.5. Spain
6.3.6. Nordics
6.3.7. BENELUX
6.3.8. Rest of Western Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2022–2029
6.4.1. U.K.
6.4.2. Germany
6.4.3. France
6.4.4. Italy
6.4.5. Spain
6.4.6. Nordics
6.4.7. BENELUX
6.4.8. Rest of Western Europe
6.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021
6.5.1. Instruments
6.5.1.1. Quantitative Pathology Imaging System
6.5.1.2. Immunofluorescence Slide Scanner
6.5.1.3. Multispectral Imaging Systems
6.5.1.4. Toponome imaging System
6.5.2. Software
6.5.3. Services
6.5.3.1. Installation & Integration Services
6.5.3.2. Maintenance Service
6.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029
6.6.1. Instruments
6.6.1.1. Quantitative Pathology Imaging System
6.6.1.2. Immunofluorescence Slide Scanner
6.6.1.3. Multispectral Imaging Systems
6.6.1.4. Toponome imaging System
6.6.2. Software
6.6.3. Services
6.6.3.1. Installation & Integration Services
6.6.3.2. Maintenance Service
6.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021
6.7.1. Immunohistochemistry (IHC) Assay
6.7.2. Fluorescent In Situ Hybridization (FISH) Assay
6.7.3. Tissue Microarray (TMA) Assay
6.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029
6.8.1. Immunohistochemistry (IHC) Assay
6.8.2. Fluorescent In Situ Hybridization (FISH) Assay
6.8.3. Tissue Microarray (TMA) Assay
6.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
6.9.1. Research
6.9.2. Clinical Diagnostics
6.10. Market Size (US$ Mn) Forecast, by Application, 2022–2029
6.10.1. Research
6.10.2. Clinical Diagnostics
6.11. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
6.11.1. Translational Laboratories
6.11.2. Biopharmaceutical Companies
6.11.3. Academic Institutes
6.12. Market Size (US$ Mn) Forecast, by Application, 2022–2029
6.12.1. Translational Laboratories
6.12.2. Biopharmaceutical Companies
6.12.3. Academic Institutes
6.13. Drivers and Restraints: Impact Analysis
6.14. Market Attractiveness Analysis
6.14.1. By Country
6.14.2. By Component Type
6.14.3. By Imaging Technique
6.14.4. Application
6.14.5. End User
6.15. Key Representative Market Presence (Intensity Map)
7. Eastern Europe Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Analysis By Country, 2012-2021
7.2.1. Russia
7.2.2. Poland
7.2.3. Rest of Eastern Europe
7.3. Market Size (US$ Mn) Forecast By Country,2022–2029
7.3.1. Russia
7.3.2. Poland
7.3.3. Rest of Eastern Europe
7.4. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021
7.4.1. Instruments
7.4.1.1. Quantitative Pathology Imaging System
7.4.1.2. Immunofluorescence Slide Scanner
7.4.1.3. Multispectral Imaging Systems
7.4.1.4. Toponome imaging System
7.4.2. Software
7.4.3. Services
7.4.3.1. Installation & Integration Services
7.4.3.2. Maintenance Service
7.5. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029
7.5.1. Instruments
7.5.1.1. Quantitative Pathology Imaging System
7.5.1.2. Immunofluorescence Slide Scanner
7.5.1.3. Multispectral Imaging Systems
7.5.1.4. Toponome imaging System
7.5.2. Software
7.5.3. Services
7.5.3.1. Installation & Integration Services
7.5.3.2. Maintenance Service
7.6. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021
7.6.1. Immunohistochemistry (IHC) Assay
7.6.2. Fluorescent In Situ Hybridization (FISH) Assay
7.6.3. Tissue Microarray (TMA) Assay
7.7. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029
7.7.1. Immunohistochemistry (IHC) Assay
7.7.2. Fluorescent In Situ Hybridization (FISH) Assay
7.7.3. Tissue Microarray (TMA) Assay
7.8. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
7.8.1. Research
7.8.2. Clinical Diagnostics
7.9. Market Size (US$ Mn) Forecast, by Application, 2022–2029
7.9.1. Research
7.9.2. Clinical Diagnostics
7.10. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
7.10.1. Translational Laboratories
7.10.2. Biopharmaceutical Companies
7.10.3. Academic Institutes
7.11. Market Size (US$ Mn) Forecast, by Application, 2022–2029
7.11.1. Translational Laboratories
7.11.2. Biopharmaceutical Companies
7.11.3. Academic Institutes
7.12. Market Attractiveness Analysis
7.12.1. By Country
7.12.2. By Component Type
7.12.3. By Imaging Technique
7.12.4. Application
7.12.5. End User
7.13. Key Representative Market Presence (Intensity Map)
8. Asia-Pacific Excluding Japan (APEJ) Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1. Drivers
8.2.2. Restraints
8.2.3. Trends
8.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2021
8.3.1. China
8.3.2. India
8.3.3. Australia and New Zealand
8.3.4. ASEAN
8.3.5. Rest of APEJ
8.4. Market Size (US$ Mn) Forecast By Country, 2022–2029
8.4.1. China
8.4.2. India
8.4.3. Australia and New Zealand
8.4.4. ASEAN
8.4.5. Rest of APEJ
8.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021
8.5.1. Instruments
8.5.1.1. Quantitative Pathology Imaging System
8.5.1.2. Immunofluorescence Slide Scanner
8.5.1.3. Multispectral Imaging Systems
8.5.1.4. Toponome imaging System
8.5.2. Software
8.5.3. Services
8.5.3.1. Installation & Integration Services
8.5.3.2. Maintenance Service
8.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029
8.6.1. Instruments
8.6.1.1. Quantitative Pathology Imaging System
8.6.1.2. Immunofluorescence Slide Scanner
8.6.1.3. Multispectral Imaging Systems
8.6.1.4. Toponome imaging System
8.6.2. Software
8.6.3. Services
8.6.3.1. Installation & Integration Services
8.6.3.2. Maintenance Service
8.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021
8.7.1. Immunohistochemistry (IHC) Assay
8.7.2. Fluorescent In Situ Hybridization (FISH) Assay
8.7.3. Tissue Microarray (TMA) Assay
8.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029
8.8.1. Immunohistochemistry (IHC) Assay
8.8.2. Fluorescent In Situ Hybridization (FISH) Assay
8.8.3. Tissue Microarray (TMA) Assay
8.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
8.9.1. Research
8.9.2. Clinical Diagnostics
8.10. Market Size (US$ Mn) Forecast, by Application, 2022–2029
8.10.1. Research
8.10.2. Clinical Diagnostics
8.11. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
8.11.1. Translational Laboratories
8.11.2. Biopharmaceutical Companies
8.11.3. Academic Institutes
8.12. Market Size (US$ Mn) Forecast, by Application, 2022–2029
8.12.1. Translational Laboratories
8.12.2. Biopharmaceutical Companies
8.12.3. Academic Institutes
8.13. Drivers and Restraints: Impact Analysis
8.14. Market Attractiveness Analysis
8.14.1. By Country
8.14.2. By Component Type
8.14.3. By Imaging Technique
8.14.4. Application
8.14.5. End User
8.15. Key Representative Market Presence (Intensity Map)
9. Japan Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029
9.1. Introduction
9.2. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021
9.2.1. Instruments
9.2.1.1. Quantitative Pathology Imaging System
9.2.1.2. Immunofluorescence Slide Scanner
9.2.1.3. Multispectral Imaging Systems
9.2.1.4. Toponome imaging System
9.2.2. Software
9.2.3. Services
9.2.3.1. Installation & Integration Services
9.2.3.2. Maintenance Service
9.3. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029
9.3.1. Instruments
9.3.1.1. Quantitative Pathology Imaging System
9.3.1.2. Immunofluorescence Slide Scanner
9.3.1.3. Multispectral Imaging Systems
9.3.1.4. Toponome imaging System
9.3.2. Software
9.3.3. Services
9.3.3.1. Installation & Integration Services
9.3.3.2. Maintenance Service
9.4. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021
9.4.1. Immunohistochemistry (IHC) Assay
9.4.2. Fluorescent In Situ Hybridization (FISH) Assay
9.4.3. Tissue Microarray (TMA) Assay
9.5. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029
9.5.1. Immunohistochemistry (IHC) Assay
9.5.2. Fluorescent In Situ Hybridization (FISH) Assay
9.5.3. Tissue Microarray (TMA) Assay
9.6. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
9.6.1. Research
9.6.2. Clinical Diagnostics
9.7. Market Size (US$ Mn) Forecast, by Application, 2022–2029
9.7.1. Research
9.7.2. Clinical Diagnostics
9.8. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
9.8.1. Translational Laboratories
9.8.2. Biopharmaceutical Companies
9.8.3. Academic Institutes
9.9. Market Size (US$ Mn) Forecast, by Application, 2022–2029
9.9.1. Translational Laboratories
9.9.2. Biopharmaceutical Companies
9.9.3. Academic Institutes
9.10. Market Attractiveness Analysis
9.10.1. By Component Type
9.10.2. By Imaging Technique
9.10.3. Application
9.10.4. End User
9.11. Key Representative Market Presence (Intensity Map)
10. Middle East and Africa Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029
10.1. Introduction
10.2. Regional Market Dynamics
10.2.1. Drivers
10.2.2. Restraints
10.2.3. Trends
10.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2021
10.3.1. GCC Countries
10.3.2. South Africa
10.3.3. Rest of MEA
10.4. Market Size (US$ Mn) Forecast By Country, 2022-2029
10.4.1. GCC Countries
10.4.2. South Africa
10.4.3. Rest of MEA
10.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021
10.5.1. Instruments
10.5.1.1. Quantitative Pathology Imaging System
10.5.1.2. Immunofluorescence Slide Scanner
10.5.1.3. Multispectral Imaging Systems
10.5.1.4. Toponome imaging System
10.5.2. Software
10.5.3. Services
10.5.3.1. Installation & Integration Services
10.5.3.2. Maintenance Service
10.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029
10.6.1. Instruments
10.6.1.1. Quantitative Pathology Imaging System
10.6.1.2. Immunofluorescence Slide Scanner
10.6.1.3. Multispectral Imaging Systems
10.6.1.4. Toponome imaging System
10.6.2. Software
10.6.3. Services
10.6.3.1. Installation & Integration Services
10.6.3.2. Maintenance Service
10.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021
10.7.1. Immunohistochemistry (IHC) Assay
10.7.2. Fluorescent In Situ Hybridization (FISH) Assay
10.7.3. Tissue Microarray (TMA) Assay
10.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029
10.8.1. Immunohistochemistry (IHC) Assay
10.8.2. Fluorescent In Situ Hybridization (FISH) Assay
10.8.3. Tissue Microarray (TMA) Assay
10.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
10.9.1. Research
10.9.2. Clinical Diagnostics
10.10. Market Size (US$ Mn) Forecast, by Application, 2022–2029
10.10.1. Research
10.10.2. Clinical Diagnostics
10.11. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021
10.11.1. Translational Laboratories
10.11.2. Biopharmaceutical Companies
10.11.3. Academic Institutes
10.12. Market Size (US$ Mn) Forecast, by Application, 2022–2029
10.12.1. Translational Laboratories
10.12.2. Biopharmaceutical Companies
10.12.3. Academic Institutes
10.13. Drivers and Restraints: Impact Analysis
10.14. Market Attractiveness Analysis
10.14.1. By Country
10.14.2. By Component Type
10.14.3. By Imaging Technique
10.14.4. Application
10.14.5. End User
10.15. Key Representative Market Presence (Intensity Map)
11. Forecast Factors: Relevance and Impact
12. Forecast Assumptions
13. Competition Landscape
13.1. Competition Dashboard
13.2. Company Share Analysis
13.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments and SWOT Analysis)
13.3.1. Perkin Elmer, Inc.
13.3.2. Bio-Rad Laboratories Inc.
13.3.3. Thermo Fisher Scientific, Inc.
13.3.4. Abcam plc.
13.3.5. Merck KGaA
13.3.6. Illumina Inc.
13.3.7. Leica Biosystems Nussloch GmbH
13.3.8. Ventana Medical Systems, Inc.
13.3.9. Aushon BioSystems Ltd.
13.3.10. MicroConstants, Inc.
13.3.11. ToposNomos Ltd.
14. Global Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029, By Region
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2021
14.2.1. North America
14.2.2. Latin America
14.2.3. Western Europe
14.2.4. Eastern Europe
14.2.5. Asia Pacific Excluding Japan
14.2.6. Japan
14.2.7. Middle East and Africa
14.3. Market Size (US$ Mn) Forecast By Region, 2022–2029
14.3.1. North America
14.3.2. Latin America
14.3.3. Western Europe
14.3.4. Eastern Europe
14.3.5. Asia Pacific Excluding Japan
14.3.6. Japan
14.3.7. Middle East and Africa
14.4. Market Attractiveness Analysis By Region
15. Global Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029, By Component Type
15.1. Introduction
15.2. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021
15.2.1. Instruments
15.2.1.1. Quantitative Pathology Imaging System
15.2.1.2. Immunofluorescence Slide Scanner
15.2.1.3. Multispectral Imaging Systems
15.2.1.4. Toponome imaging System
15.2.2. Software
15.2.3. Services
15.2.3.1. Installation & Integration Services
15.2.4. Maintenance Service
15.3. Market Size (US$ Mn) and Volume Forecast By Component Type,2022–2029
15.3.1. Instruments
15.3.1.1. Quantitative Pathology Imaging System
15.3.1.2. Immunofluorescence Slide Scanner
15.3.1.3. Multispectral Imaging Systems
15.3.1.4. Toponome imaging System
15.3.2. Software
15.3.3. Services
15.3.3.1. Installation & Integration Services
15.3.4. Maintenance Service
15.4. Market Attractiveness Analysis by Component Type
16. Global Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis, by Imaging Technique, 2012-2021
16.2.1. Immunohistochemistry (IHC) Assay
16.2.2. Fluorescent In Situ Hybridization (FISH) Assay
16.2.3. Tissue Microarray (TMA) Assay
16.3. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029
16.3.1. Immunohistochemistry (IHC) Assay
16.3.2. Fluorescent In Situ Hybridization (FISH) Assay
16.3.3. Tissue Microarray (TMA) Assay
16.4. Market Attractiveness Analysis by Imaging Technique
17. Global Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029, By Application
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis, by Application, 2012-2021
17.2.1. Research
17.2.2. Clinical Diagnostics
17.3. Market Size (US$ Mn) Forecast, by Application, 2022–2029
17.3.1. Research
17.3.2. Clinical Diagnostics
17.4. Market Attractiveness Analysis by Application
18. Global Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029, By End User
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis, by End User, 2012-2021
18.2.1. Translational Laboratories
18.2.2. Biopharmaceutical Companies
18.2.3. Academic Institutes
18.3. Market Size (US$ Mn) Forecast, by End User, 2022–2029
18.3.1. Translational Laboratories
18.3.2. Biopharmaceutical Companies
18.3.3. Academic Institutes
18.4. Market Attractiveness Analysis by End User
19. Global Market Analysis 2012-2021 and Forecast 2022–2029
19.1. Market Size and Y-o-Y Growth
19.2. Absolute $ Opportunity
20. Assumptions and Acronyms Used
21. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: CPT Codes for Digital Pathology
Table 02: DPA Regulatory FDA 510(k) List
Table 03: DPA Regulatory FDA 510(k) List
Table 04: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 05: North America Multiplex Biomarker Imaging Market Volume Analysis 2012-2021 and Forecast 2022–2029, By Component Type
Table 06: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique
Table 07: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 08: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User
Table 09: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Table 10: North America Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)
Table 11: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 12: Latin America Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 13: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique
Table 14: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 15: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User
Table 16: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Table 17: Latin America Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)
Table 18: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 19: Western Europe Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 20: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique
Table 21: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 22: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User
Table 23: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Table 24: Western Europe Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)
Table 25: Eastern Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 26: Eastern Europe Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 27: Eastern Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique
Table 28: Eastern Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 29: Eastern Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User
Table 30: Eastern Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Table 31: Eastern Europe Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)
Table 32: APEJ Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 33: APEJ Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 34: APEJ Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique
Table 35: APEJ Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 36: APEJ Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User
Table 37: APEJ Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Table 38: APEJ Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)
Table 39: Japan Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 40: Japan Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 41: Japan Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique
Table 42: Japan Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 43: Japan Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User
Table 44: Japan Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)
Table 45: MEA Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 46: MEA Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 47: MEA Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique
Table 48: MEA Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 49: MEA Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User
Table 50: MEA Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country
Table 51: MEA Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)
Table 52: Global Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Region
Table 53: Global Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 54: Global Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type
Table 55: Global Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique
Table 56: Global Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application
Table 57: Global Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: U.S FDA Regulatory Approval for Medical Devices
Figure 02: Europe Regulatory Approval for Medical Devices
Figure 03: Japan Regulatory Approval for Medical Devices
Figure 04: North America Multiplex Biomarker Imaging Market Value Share by Component Type (2022)
Figure 06: North America Multiplex Biomarker Imaging Market Value Share by Application (2022)
Figure 05: North America Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)
Figure 07: North America Multiplex Biomarker Imaging Market Value Share by End User (2022)
Figure 08: North America Multiplex Biomarker Imaging Market Value Share by Country (2022)
Figure 09: North America Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 10: North America Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 11: U.S. Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 12: U.S. Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 13: Canada Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 14: Canada Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 15: North America Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029
Figure 16: North America Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029
Figure 17: North America Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029
Figure 18: North America Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029
Figure 19: North America Multiplex Biomarker Imaging Market Attractive Analysis by Country, 2022–2029
Figure 20: North America - Drivers & Restrains Impact Analysis
Figure 21: Latin America Multiplex Biomarker Imaging Market Value Share by Component Type (2022)
Figure 23: Latin America Multiplex Biomarker Imaging Market Value Share by Application (2022)
Figure 22: Latin America Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)
Figure 24: Latin America Multiplex Biomarker Imaging Market Value Share by End User (2022)
Figure 25: Latin America Multiplex Biomarker Imaging Market Value Share by Country (2022)
Figure 26: Latin America Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 27: Latin America Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 28: Brazil Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 29: Brazil Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 30: Mexico Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 31: Mexico Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 32: Argentina Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 33: Argentina Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 34: Rest of Latin America Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 35: Rest of Latin America Multiplex Biomarker Imaging Market Forecast, 2012 - 2021
Figure 36: Latin America Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029
Figure 37: Latin America Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029
Figure 38: Latin America Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029
Figure 39: Latin America Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029
Figure 40: Latin America Multiplex Biomarker Imaging Market Attractive Analysis by Country, 2022–2029
Figure 41: Latin America - Drivers & Restraint Impact Analysis
Figure 42: Western Europe Multiplex Biomarker Imaging Market Value Share by Component Type (2022)
Figure 44: Western Europe Multiplex Biomarker Imaging Market Value Share by Application (2022)
Figure 43: Western Europe Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)
Figure 45: Western Europe Multiplex Biomarker Imaging Market Value Share by End User (2022)
Figure 46: Western Europe Multiplex Biomarker Imaging Market Value Share by Country (2022)
Figure 47: Western Europe Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 48: Western Europe Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 49: U.K. Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 50: U.K. Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 51: Germany Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 52: Germany Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 53: France Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 54: France Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 55: Italy Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 56: Italy Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 57: Spain Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 58: Spain Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 59: Nordics Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 60: Nordics Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 61: Benelux Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 62: Benelux Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 63: Rest of Western Europe Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 64: Rest of Western Europe Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 65: Western Europe Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029
Figure 66: Western Europe Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029
Figure 67: Western Europe Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029
Figure 68: Western Europe Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029
Figure 69: Western Europe Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029
Figure 70: Europe - Drivers & Restraint Impact Analysis
Figure 70: Eastern Europe Multiplex Biomarker Imaging Market Value Share by Component Type (2022)
Figure 72: Eastern Europe Multiplex Biomarker Imaging Market Value Share by Application (2022)
Figure 71: Eastern Europe Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)
Figure 73: Eastern Europe Multiplex Biomarker Imaging Market Value Share by End User (2022)
Figure 74: Eastern Europe Multiplex Biomarker Imaging Market Value Share by Country (2022)
Figure 75: Eastern Europe Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 76: Eastern Europe Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 77: Russia Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 78: Russia Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 79: Poland Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 80: Poland Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 81: Rest of Eastern Europe Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 82: Rest of Eastern Europe Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 83: Eastern Europe Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029
Figure 84: Eastern Europe Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029
Figure 85: Eastern Europe Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029
Figure 86: Eastern Europe Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029
Figure 87: Eastern Europe Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029
Figure 88: APEJ Multiplex Biomarker Imaging Market Value Share by Component Type (2022)
Figure 90: APEJ Multiplex Biomarker Imaging Market Value Share by Application (2022)
Figure 89: APEJ Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)
Figure 91: APEJ Multiplex Biomarker Imaging Market Value Share by End User (2022)
Figure 92: APEJ Multiplex Biomarker Imaging Market Value Share by Country (2022)
Figure 93: APEJ Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 94: APEJ Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 95: China Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 96: China Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 97: India Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 98: India Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 99: Australia and NZ Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 100: Australia and NZ Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 101: ASEAN Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 102: ASEAN Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 103: Rest of APEJ Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 104: Rest of APEJ Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 105: APEJ Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029
Figure 106: APEJ Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029
Figure 107: APEJ Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029
Figure 108: APEJ Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029
Figure 109: APEJ Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029
Figure 110: APAC - Drivers & Restraint Impact Analysis
Figure 111: Japan Multiplex Biomarker Imaging Market Value Share by Component Type (2022)
Figure 113: Japan Multiplex Biomarker Imaging Market Value Share by Application (2022)
Figure 112: Japan Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)
Figure 114: Japan Multiplex Biomarker Imaging Market Value Share by End User (2022)
Figure 115: Japan Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 116: Japan Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 117: Japan Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029
Figure 118: Japan Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029
Figure 119: Japan Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029
Figure 120: Japan Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029
Figure 121: MEA Multiplex Biomarker Imaging Market Value Share by Component Type (2022)
Figure 123: MEA Multiplex Biomarker Imaging Market Value Share by Application (2022)
Figure 122: MEA Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)
Figure 124: MEA Multiplex Biomarker Imaging Market Value Share by End User (2022)
Figure 125: MEA Multiplex Biomarker Imaging Market Value Share by Country (2022)
Figure 126: MEA Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 127: MEA Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 128: South Africa Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 129: South Africa Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 130: GCC Countries Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 131: GCC Countries Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 132: Rest of MEA Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 133: Rest of MEA Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 134: MEA Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029
Figure 135: MEA Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029
Figure 136: MEA Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029
Figure 137: MEA Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029
Figure 138: MEA Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029
Figure 139: MEA Drivers & Restraint Impact Analysis
Figure 140: Global Multiplex Biomarker Imaging Market Share Analysis
Figure 141: Global Multiplex Biomarker Imaging Market Attractive Analysis by Region, 2022–2029
Figure 142: Global Multiplex Biomarker Imaging Market Attractive Analysis by Component, 2022–2029
Figure 143: Global Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Techniques, 2022–2029
Figure 144: Global Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029
Figure 145: Global Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029
Figure 146: Global Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021
Figure 147: Global Multiplex Biomarker Imaging Market Forecast, 2022 - 2029
Figure 148: Global Multiplex Biomarker Imaging Market Absolute $ Opportunity, 2012 - 2021
Figure 149: Global Multiplex Biomarker Imaging Market Absolute $ Opportunity, 2022 – 2029
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
